Sanofi completes acquisition of Bioverativ


Sanofi announced the successful completion of its acquisition of Bioverativ for $105 per share in cash

Commenting on the acquistion, Olivier Brandicourt Sanofi's CEO said: "The addition of Bioverativ provides us with a strong position in the large and growing hemophilia market and expands our presence in specialty care," said ," Sanofi's CEO.

"Through a series of three strategic transactions the addition of Bioverativ, our planned acquisition of Ablynx and our agreement for fitusiran, we are well on our way to creating a leading franchise in the field of rare blood disorders."

Sign up for your free email newsletter

Sanofi and its wholly-owned subsidiaries, Sanofi-Aventis and Blink Acquisition, accepted for payment and will promptly pay for all shares validly tendered.